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Hepatitis C virus (HCV) infected patients are known to be exposed to major liver complications
i.e. cirrhosis and hepatocellular carcinoma. In addition, many extrahepatic manifestations
including rheumatologic disorders have been reported in up to two-third of HCV infected
patients. These manifestations include frank auto-immune and rheumatic diseases (such as
arthralgia, myalgia, arthritis, sicca syndrome and vasculitis) which may dominate the course






Treatmentof infection. Until recently, the standard of care of HCV has been the use of interferon-alpha
based regimens, which not only had limited effectiveness in HCV cure but were poorly tolerated.
In patients with rheumatic diseases interferon-based regimens may be problematic given their
association with a wide variety of autoimmune toxicities. Recent therapeutic advances with
new direct anti-HCV therapies (interferon-free) which are more effective and better tolerated,
make screening for this comorbidity in patients with rheumatic disorders more important than
ever. This review aimed to outline main HCV extrahepatic with a special focus on rheumato-
logic manifestations.
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Hepatitis C Virus (HCV) infection, a major global health
problem leading to heavy costs, is present in 150–170 million
people, including 19 million people in Europe [1]. Liver com-
plications, including cirrhosis and liver cancer, are currently
reported during chronic HCV infection, with an estimated
liver-related mortality of 350,000 people/year. Additionally,
extrahepatic manifestations are presented in up to two-
third of patients [2]. Several of these manifestations are com-
mon and well-described while others are infrequent [3–5]. In
the literature, autoimmune and lymphoproliferative diseases
are well-known HCV-related disorders [6]. Other more
recently reported HCV-associated disorders include cardio-
metabolic, renal, and neurocognitive disorders. With the
arrival of direct acting antivirals (DAAs), the perspective
of HCV eradication is important in a therapeutic and pre-
ventive aspect, for liver and non-liver consequences of the
disease. This review aimed to outline most of rheumatologicHCV extrahepatic manifestations that are currently deeper
investigated.
Cryoglobulinemia vasculitis
Mixed cryoglobulinemia vasculitis (CryoVas) is a systemic vas-
culitis which leads to clinical manifestations ranging from pur-
pura, arthralgia and fatigue to more serious lesions with
neurologic and renal involvement [7]. Circulating mixed cryo-
globulins are detected in 40–60% of patients chronically
infected with HCV whereas overt CryoVas is observed in only
5–10% of cases. HCV infection represents the cause of Cryo-
Vas in 70–80% of cases [7–9]. The disease expression may
range from mild symptoms to fulminant life-threatening com-
plications. The main skin symptom is a palpable purpura;
chronic cutaneous ulcers, Raynaud’s phenomenon, acro-
cyanosis, and digital ulcerations can also occur [7]. Patients
present with arthralgia of large peripheral joints in 70% of
cases, rarely with arthritis. The most frequently described neu-
rologic manifestation is a distal sensory or sensory-motor
polyneuropathy, with painful, asymmetric paresthesia. Multi-
ple mononeuropathy may occur less frequently. An acute or
chronic membranoproliferative glomerulonephritis with sub-
endothelial deposits represents the large majority of
cryoglobulinemia-renal diseases, strongly linked with the type
II IgM kappa mixed cryoglobulinemia (MC). It presents usu-
ally with proteinuria, hematuria and a variable intensity of
renal insufficiency.
Cryoglobulinemia is defined as the presence protein which
precipitates in the serum at 4 C during 7 days and which dis-
solved at 37 C. During chronic HCV infection, mixed cryo-
globulinemia are characterized as type II or type III
cryoglobulins which consist of polyclonal IgG with mono-
clonal or polyclonal IgM with rheumatoid factor (RF) activity,
respectively [10]. During follow-up, improvement is assessed
by the serum level of cryoglobulinemia and surrogate markers
(C4, CH50, RF).
Main predictive factors of CryoVas in HCV-infected
patients are advanced age, longer duration of infection, type
II mixed cryoglobulin, and clonal B-cell expansions in both
the blood and liver. The worse pronostic factors are an age
older than 60 years and renal manifestations, with a 5 year sur-
vival ranging from 90% to 50% in case of kidney involvement.
Other causes of mortality include liver disease, cardiovascular
disease, infectious disease and lymphoma [11]. Among 231
patients, 79 of 97 deaths were linked to vasculitis (46%), can-
cer/hemopathy (23%), or liver disease (13%) [12]. HCV-
CryoVas may result in progressive (renal involvement) or acute
(gut, cardiac, CNS, pulmonary hemorrhage) life-threatening
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[13,14].
Multiple factors predispose patients to develop a CryoVas.
HCV-lymphocytes interaction directly modulates B- and T-cell
function and results in polyclonal activation and expansion of
B-cell producing IgM with RF activity [15]. Regulatory T cell,
known to control self-tolerance, is reduced in HCV-CryoVas
patients. Regulatory T cell deficiency may contribute to
autoreactive B-cell expansion driving autoimmune manifesta-
tions in HCV-CryoVas patients [16,17]. HLA-DR11 increases
the risk of CryoVas whereas HLA-DR7 decreases the risk of
type II mixed cryoglobulin production [18]. A SNP within an
intronic region of NOTCH4 (p= 6.2 * 10–9) and another
between HLA-DRB1 and HLA–DQA1 (p= 1.2 * 10–7) on
chromosome 6 were associated with HCV-CryoVas [19]. A
high prevalence of homozygosity and a great frequency of a
particular allele of the BAFF promoter were found in HCV-
CryoVas patients compared to HCV patients [20]. Different
expression profiles of microRNAs in peripheral blood
mononuclear cell associated with lymphoproliferative and
autoimmune disorders have been reported [21]. Today, no
specific virologic factors have been found.
Most HCV-CryoVas manifestations have been shown to
disappear after HCV clearance post antiviral therapy with
pegylated interferon (IFN) plus ribavirin [22,23] whereas viro-
logical relapsers usually relapse for the CryoVas [24]. Current
treatment of HCV-CryoVas is guided by organ involvement
and the severity of the disease (Fig. 1). In case of persistent
CryoVas manifestations in patients with a sustained virologic
response (SVR), another underlying condition should be con-
sidered, especially B-cell lymphoma [25]. Combination therapy
with pegylated-IFN/ribavirin plus a NS3/4A protease inhibitor
(boceprevir or telaprevir) showed at week 24 post-treatment
that 20/30 (67%) patients were complete clinical and SVRs
[26], with serious adverse events almost fifty percent. Use of
Peg-IFN/ribavirin in combination with boceprevir for
48 weeks in 35 HCV GT1 patients showed a drastic reduction
of the cryocrit values, and an improvement of CryoVas symp-
toms [27]. New interferon-free DAAs are now available which
facilitate shortened courses of IFN-free antivirals associated
with SVR rates >95% and few side effects. InternationalFig. 1 Therapeutic strategguidelines (i.e., EASL 2015) [28] state that treatment should
be scheduled, not deferred, for patients with clinically signifi-
cant extra-hepatic manifestations, like CryoVas. In a recent
French study, sofosbuvir (400 mg/day) plus ribavirin (200–
1400 mg/day) combination for 24 weeks was associated with
a high rate of complete clinical response of CryoVas (87.5%)
and a low rate of serious adverse events (8.3%) [29]. Other
recent studies report both safety and efficacy of IFN-free
DAA antivirals including non SOF-based regimens, in
difficult-to-treat patients [30,31]. Sise et al. [32] have reported
a retrospective case series of twelve HCV-CryoVas patients
treated with SOF-based regimens [median age 61 years, 58%
male, 50% cirrhotic]. All patients had undetectable HCV
RNA by week 4. A SVR12 was achieved in 10/12 (83%)
patients. Individual eGFR changes showed a positive impact
in two out of seven patients with active glomerulonephritis;
there was a reduction in proteinuria in 3/3 cases. Only two
(17%) patients experienced serious adverse events.
Rituximab has proved a clear benefit in CryoVas as it tar-
gets B-cells which are responsible for cryoglobulin production
[33–37]. In a randomized trial rituximab showed a better effi-
cacy than conventional immunosuppressants [38]. Similar
results have been reported in a placebo controlled trial [39].
There was no risk of viral reactivation in HCV patients, con-
trary to HBV infection [40]. Rituximab plus pegylated-IFN/
ribavirin compared to pegylated-IFN/ribavirin led to a shorter
time to clinical remission, better renal response rate, and
higher rates of cryoglobulin clearance [41,42].
To summarize, in HCV-CryoVas with mild to moderate
disease, an optimal antiviral IFN-free treatment should be
given alone. For patients with severe vasculitis (i.e. worsen-
ing of renal function, mononeuritis multiplex, extensive skin
disease, and intestinal ischemia) control of disease with
rituximab, with or without plasmapheresis, is usually
required and antiviral IFN-free therapy should be started
at the same time [43]. Low-dose corticosteroids may help
to control inflammatory signs such arthralgia but do not
succeed in case of major organ involvement. Other immuno-
suppressants should be given only in case of refractory
forms of CryoVas, frequently associated with underlying
B-cell lymphoma [44].ies in HCV-CryoVasc.
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Initially, few cohorts reported a high prevalence of HCV infec-
tion in patients with B-cell non-Hodgkin’s lymphoma (B-
NHL) [45,46], then this observation was confirmed in meta-
analyses [47–51]. HCV chronic infection was associated with
marginal zone B-NHL (OR 2.47) and diffuse large B-NHL
(OR 2.24). A serum IgMk gammopathy has been frequently
noted in HCV patients [52].
In addition, incidence of B-NHL was lower in patients with
SVR [53]. A SVR was associated with NHL regression while a
viral relapse was followed by the lymphoma relapse [54,55].
HCV-positive splenic lymphoma with villous lymphocytes
(SLVL) regressed after antiviral therapy [56]. Regression of
clonal B-cell expansion following successful antiviral therapy
has been described with novel expansion of the same clones
in patients who relapsed [57,58]. This suggests no-return points
in the HCV-driven lymphomagenesis, making the pathogenic
mechanism progressively less dependent on the viral antigen
[59].
HCV-related lymphoproliferative diseases appear to be the
result of multiple events such as a sustained B-cells activation,
an aberrant B-cell survival, genetic/epigenetic and environ-
mental factors [59,60]. The role of a prolonged antigenic stim-
ulation has been demonstrated by the lymphotropism of HCV
and the presence of HCV antigens in peripheral blood or liver
infiltrating lymphocytes and lymph-nodes [61–63]. The linking
of HCV surface E2 protein with the tetraspanin CD81 dimin-
ished B-cell activation threshold [64]. BCR sequence analyses
and affinity in HCV-related NHL showed conflicting results
[65,66]. Higher prevalence of HCV infection in PBMCs and
bone marrow [67,68] and in vitro studies support the lym-
photropism of the virus [69,70]. The rate of mutations in onco-
genes and immunoglobulin genes is increased in HCV-infected
cells [71]. The expression of HCV core and lymphoma was cor-
related in transgenic models [72,73]. The (14;18) translocation
increased Bcl-2 levels and B-cell survival [58,74,75] that disap-
peared after antivirals [57,76,77]. The role of cytokines and
chemokines [15,78–81], including BAFF [20,60,82–84], and
the role of microRNAs [21,85] have been studied extensively
in HCV-related lymphoproliferative diseases.
Several studies showed a clinical remission following antivi-
rals in low-grade B-cell NHL, mainly in marginal zone lym-
phoma [55,56,86–89]. The use of IFN-based therapy in
patients with indolent HCV-NHL has been associated with
an improved overall survival [89]. IFN-based treatment is dif-
ficult because of IFN hematological toxicity. However, antivi-
rals after lymphoma remission showed prolonged disease-free
survival [90,91]. Rituximab alone or with antivirals and/or
chemotherapy showed good results in low-grade B-NHL
[42,92]. The recent availability of IFN-free DAAs with a high
virological efficacy and no hematological toxicity should easily
permit their association with chemotherapy, taking into
account possible pharmacological interference.Arthralgia/myalgia
Arthralgia are found in 30–70% of HCV-infected patients with
mixed cryoglobulin [3,93]. Patients present with bilateral, sym-
metric, non-deforming joint pains involving mainly knees and
hands, more rarely elbows and ankles. HCV arthritis, unlinkedto mixed cryoglobulin, is uncommon (<10%). A RF activity
is found in 70–80% of CryoVas patients due to the presence
of a mixed cryoglobulin; it is not associated with the presence
or the activity of joint manifestations. Radiographic joint
destruction is not found. Search for antibodies to cyclic citrul-
linated peptide is negative. IFN-based combinations for HCV
may exacerbate arthralgia and myalgia, thus confounding
clinical presentation. Clinicians should use main characteristics
to differentiate rheumatologic manifestations such as arthral-
gia, myalgia, and arthritis that may occur in HCV infected
patients due to HCV infection itself or to a newly developed
rheumatologic disease.
Sicca syndrome
An ocular and/or buccal sicca syndrome is described in 20–
30% of HCV infected patients, whereas a definite Sjo¨gren’s
syndrome (xerostomia, xerophthalmia, anti-SSA/anti-SSB
antibodies and typical salivary gland histology) is reported in
less than 5% of HCV-positive patients [3]. The presentation
may be confusing between HCV-related sicca syndrome and
‘‘true” Sjo¨gren’s syndrome [94]. HCV-positive patients with a
Sjo¨gren’s syndrome are older and more likely to have a photo-
sensitivity and a mixed cryoglobulinemia compared to those
with a primary Sjo¨gren’s syndrome. Presence of low titers of
antinuclear antibodies and a RF are common in HCV patients
with sicca syndrome, and the presence of Sjo¨gren’s syndrome
autoantibodies (i.e. anti-SSA/SSB antibody) is rare. The
sialadenitis found in HCV infected patients may be related
to the allotropism of the virus [95]. In transgenic mice, the
development of sialadenitis has been associated with the
expression of E1- and E2-HCV glycoproteins [96].
Auto-antibodies
HCV infected patients are frequently positive for autoantibod-
ies (up to 53%), i.e. mixed cryoglobulins (60–80%), RF activ-
ity (70%), and antinuclear (20–40%), anticardiolipin (aCL)
(20–15%), anti-thyroid (12%) and anti-smooth muscle anti-
bodies (7%) [2,3]. Such autoantibodies have not been associ-
ated with connective tissue disease manifestations, except for
mixed cryoglobulins and CryoVas. For example, while aCL
occurs frequently in viral infections, particularly in HIV
(49.75%), HBV (24%) and HCV (20–15%), they are very
rarely associated with anti-beta2 glycoprotein I antibodies
and are not correlated with a thrombotic risk [97]. In patients
with non-autoimmune liver diseases, the production of aCL is
a non-specific phenomenon of the liver damage, and it is not
associated with thrombotic complications [98]. The HCV-
induced activation and proliferation of B cells is the most
reported reason for such auto-antibody production, although
many other auto-antibodies are not found in HCV infected
patients.
Renal insufficiency
The more frequent and severe renal manifestations in HCV
infected patients are related to CryoVas (see above). However
other mechanisms may be involved leading to renal involve-
ment in such patients. A higher rate of MPGN was found in
HCV-positive compared to HCV-negative U.S. hospitalized
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branous glomerulopathy (0.33% vs. 0.19%, P= 0.86) [99].
A higher rate of renal insufficiency has been reported in
HCV infected patients compared with subjects without HCV
infection, after adjusting for age, gender, race, diabetes, and
hypertension [100]. HCV infection may affect renal function
in the general population as it has been associated with low
GFR, with odds ratio up to 2.80 [101]. In addition, HCV infec-
tion appears to increase the risk of proteinuria in healthy indi-
viduals, with odds ratio of 1.14–1.99, independently of
diabetes mellitus, arterial hypertension, obesity, and dyslipi-
demia [102–106].
Increased non liver-related mortality/morbidity, i.e.
cardiovascular and glucose metabolism disorders
The main cause of mortality in HCV infected patients is the
liver disease [107–113]. However, HCV infected patients
showed increased mortality rates due to extra-hepatic compli-
cations (i.e., cardiovascular, renal, tumoral) [111,112,114–116].
Some chronic infections have been suggested as triggers for
cardiovascular diseases [117–119]. Their identification as car-
diovascular risk factors may offer new perspectives in cardio-
vascular disease prevention [120]. HCV seropositivity is
associated with high rates of carotid-artery plaques, carotid
intima-media thickening, and the risk of stroke independently
of other well known atherosclerosis risk factors [117]. The
HCV is able to induce the production of pro-atherogenic
cytokines [121] that may promote the atherosclerotic plaque
instability, supporting a role of the virus in the cerebrovascular
diseases risk [122]. In addition, cohort studies suggested a pos-
itive impact of antivirals on the incidence of stroke [123].
HCV infection has been shown to increase the risk of coro-
nary artery disease, after adjustment for cardiovascular risk
factors [124]. Patients with SVR after antivirals showed an
improvement in their myocardial perfusion defect whereas
relapsers showed a worsening after a transient improvement
[125]. The risk of major cardiovascular events (i.e. cerebrovas-
cular accident and ischemic heart disease) is higher in patients
with HCV infection compared to controls, independent of the
severity of the liver disease or the common cardiovascular risk
factors [126]. The beneficial impact of IFN-based therapy
needs to be confirmed with new IFN-free DAAs in prospective
studies with extended follow-up.
Insulin-resistance, commonly associated with obesity and
metabolic syndrome, can evolve to diabetes mellitus [127].
The presence of insulin-resistance has been analyzed in SVRs
after pegylated IFN plus ribavirin. On one hand, the therapeu-
tic response was not altered by insulin-resistance. On the other
hand, therapeutic failure and elevated body mass index were
independent risk factors for de novo appearance of insulin-
resistance after treatment. No new case of insulin-resistance
was registered in SVR patients, suggesting a possible preven-
tion of insulin-resistance onset and its evolution to diabetes
[128]. Insulin resistance has been found to alter SVR rate to
pegIFN plus ribavirin in HIV-HCV coinfected patients [129].
Increased risk of type 2 diabetes in HCV infected patients
may arise from interactions between insulin resistance, steato-
sis and inflammatory mechanisms [130]. Many epidemiologic
studies support the link between type 2 diabetes and HCV
infection [131,132,133]. Type 2 diabetes was more frequent inHCV- than HBV-related cirrhosis (23.6% vs. 9.4%; OR 2.78;
95%CI, 1.6–4.79; P= 0.0002) [134,135]. In HCV infected
patients type 2 diabetes was more frequent in male cirrhotics.
The prevalence and spectrum of rheumatic disorders and
autoimmune phenomena in HCV-infected patients have been
reported [8,136]. Many of these extrahepatic manifestations
are autoimmune disorders, with added mortality and
morbidity due to involvement of multiple organ systems
[137]. Until recently, the standard of care of HCV has been
the use of interferon-based regimens, which not only have lim-
ited effectiveness in curing the underlying viral illness but are
poorly tolerated and in patients with rheumatic diseases espe-
cially problematic given their association with a wide variety of
autoimmune toxicities [138]. CryoVasc can be treated at differ-
ent levels by means of etiological treatment with antivirals
aimed at HCV eradication and/or pathogenetic/symptomatic
treatments directed to both immune-system alterations and
the vasculitic process (rituximab, cyclophosphamide, steroids,
plasmapheresis) [133]. In clinical practice, the therapeutic
strategy should be modulated according to severity/activity
of the CryoVasc and possibly tailored to each individual
patient’s conditions. In our review, we investigated clinical
and therapeutic facets of HCV-related extrahepatic
manifestations.
Conclusions
In summary, beyond the liver manifestations, HCV chronic
infection frequently leads to a true systemic disease where
many manifestations appear to be in the field of rheumatology.
Therefore, rheumatologists should be aware of these numerous
manifestations and they should increase the screening of HCV
infection in their patients.
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